Cryoport and VGXI, a subsidiary of GeneOne Life Science, announced a strategic partnership to support biopharmaceutical companies in developing cell and gene therapies and mRNA-based treatments. VGXI is a contract developer and manufacturer specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines and RNA medicines, and ADC applications. Through this new partnership, Cryoport Systems will provide biostorage and bioservices from its Houston, Texas, facility for plasmid DNA products manufactured at VGXI’s facilities in The Woodlands, Texas, and its new headquarters and manufacturing location in Conroe, Texas. Partnership operations are set to commence in October 2024.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX: